ID 110163
Author
Shoda, Katsutoshi Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine
Ichikawa, Daisuke Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine
Fujita, Yuji Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine|Department of Human Genetics, Graduate School of Biomedical Sciences, Tokushima University
Masuda, Kiyoshi Department of Human Genetics, Graduate School of Biomedical Sciences, Tokushima University KAKEN Search Researchers
Hiramoto, Hidekazu Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine
Hamada, Junichi Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine
Arita, Tomohiro Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine
Konishi, Hirotaka Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine
Kosuga, Toshiyuki Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine
Komatsu, Shuhei Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine
Shiozaki, Atsushi Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine
Okamoto, Kazuma Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine
Imoto, Issei Department of Human Genetics, Graduate School of Biomedical Sciences, Tokushima University Tokushima University Educator and Researcher Directory KAKEN Search Researchers
Otsuji, Eigo Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine
Content Type
Journal Article
Description
Recent comprehensive molecular subtyping of gastric cancer (GC) identified Epstein–Barr virus (EBV)-positive tumors as a subtype with distinct salient molecular and clinical features. In this study, we aimed to determine the potential utility of circulating cell-free EBV DNA as a biomarker for the detection and/or monitoring of therapeutic response in patients with EBV-associated gastric carcinoma (EBVaGC). The EBV genes-to-ribonuclease P RNA component H1 ratios (EBV ratios) in the GC tumors and plasma samples were determined by quantitative real-time polymerase chain reaction in 153 patients with GC, including 14 patients with EBVaGC diagnosed by the conventional method. Circulating cell-free EBV DNA was detected in 14 patients with GC: the sensitivity and specificity of detection were 71.4% (10/14) and 97.1% (135/139), respectively. Plasma EBV ratios were significantly correlated with the size of EBVaGC tumors, and the plasma EBV DNA detected before surgery in EBVaGC cases disappeared after surgery. Patients with EBVaGC may have a better prognosis, but circulating cell-free EBV DNA had no or little impact on prognosis. In addition, repeated assessment of the plasma EBV ratio in EBVaGC showed a decrease and increase in plasma EBV DNA after treatment and during tumor progression/ recurrence, respectively. These results suggest the potential utility of circulating cell-free DNA to reveal EBV DNA for the identification of the EBVaGC subtype and/ or for real-time monitoring of tumor progression as well as treatment response in patients with EBVaGC.
Journal Title
Oncotarget
ISSN
19492553
Volume
8
Issue
17
Start Page
28796
End Page
28804
Sort Key
28796
Published Date
2017-02-24
Remark
Copyright: Shoda et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC-BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
EDB ID
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
Publisher
departments
Medical Sciences